Business
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting
Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on
About this update from Inmune Bio Inc.
[{"type":"text","content":"Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, being held in a hybrid format (in-person and virtual) from November 9-12 in Boston. Details of the presentations are as follows: Late-breaking oral presentation: Title: The Early Mild Alzheimer’s Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595 in Alzheimer’s Disease (AD) with inflammation (ADi) Presenter: Dr. Judith Jaeger, Cognitionmetrics and Albert Einstein College of Medicine, Stamford, CT and Bronx, NY Session: LB12 Date: Friday, November 12 (onsite) Time: 9:55am ET Late-breaking oral communication: Title: Analyzing the CSF proteome to support decisions in an AD clinical trial program Theme: Clinical trials: biomarkers including plasma Poster (on-demand/virtual): LBR7 Date: Tuesday, November 9 Time: presentation will be available beginning at 8:00am ET Poster presentations: Title: Novel white matter imaging measures of neuroinflammation, axonal density and demyelination as potential biomarkers for trials in the AD spectrum: validation in the largescale longitudinal multicenter ADNI studies Theme: Clinical trials: imaging Poster (onsite): LP3 Time: all posters will be available beginning November 9 at 8:00am ET Title: MRI measures of white matter pathology can replace CSF sampling in AD clinical trials – case study from the XProTM a phase 1 trial in Alzheimer’s patients with neuroinflammation Theme: Clinical trials: imaging Poster (onsite): LP4 Time: all posters will be available beginning November 9 at 8:00am ET Title: Planning for Success: a Three-step process to Define Phase II Trial Size and Duration Using a Patient Enrichment Strategy using Phase I Data and Public Databases Theme: Clinical trials: methodology Poster (onsite): LP11 Time: all posters will be available beginning November 9 at 8:00am ET About XPro XPro is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and differentiates itself from existing TNF inhibitors in that it neutralizes s...